Welcome to our dedicated page for Aspire Biopharma Holdings news (Ticker: ASBPW), a resource for investors and traders seeking the latest updates and insights on Aspire Biopharma Holdings stock.
Aspire Biopharma Holdings, Inc. reports developments tied to its sublingual delivery technology, consumer caffeine subsidiary, and public-company status. The company has described patent-pending technology designed to deliver active pharmaceutical ingredients and other bioactive substances through sublingual absorption, including work on rapid-delivery powder formulations.
Recent company news also centers on Buzz Bomb Caffeine Company, a wholly owned subsidiary that markets BUZZ BOMB, a single-serving dry powder caffeine product designed for under-the-tongue use. Recurring updates include retail distribution relationships, convenience-store packaging, health and fitness marketing, sales and public-relations appointments, product positioning, development collaborations, and Nasdaq listing-compliance matters.
Aspire Biopharma (Nasdaq:ASBP) filed a provisional USPTO patent application on February 12, 2026 for a sublingual powder formulation of ondansetron, aimed at rapid relief of chemotherapy-, radiation- and surgery-induced nausea.
The company highlights potential near-instant absorption versus 30-minute oral tablets, plans to pursue an FDA 505(b)(2) pathway, and cites >12.5 million U.S. prescriptions and a ~$1.4B global market (2023).
Aspire Biopharma (Nasdaq:ASBP) entered a securities purchase agreement to sell up to 26,250 Series A convertible preferred shares at $800 per share for aggregate gross proceeds of up to $21.0 million. An initial closing on February 6, 2026 issued 13,750 shares for $11.0 million.
Proceeds will repay legacy indebtedness, support operations and strategic initiatives, and are expected to help the company regain compliance with Nasdaq stockholders' equity requirements. A second closing is subject to customary conditions. RBW Capital Partners acted as sole placement agent.
Aspire Biopharma (Nasdaq: ASBP) regained compliance with Nasdaq Listing Rule 5550(a)(2) after achieving a closing bid of at least $1.00 per share for 10 consecutive business days, and Nasdaq confirmed the matter is closed on February 10, 2026.
The company remains subject to an extension to evidence compliance with the $2.5 million stockholders' equity requirement and says it has made progress on strategic plans for 2026 with additional details to follow.
Aspire Biopharma (NASDAQ:ASBP) subsidiary Buzz Bomb Caffeine Company will showcase its flagship BUZZ BOMB™ sublingual caffeine at The Sports & Active Nutrition Summit USA in San Diego on February 18-20, 2026. The product delivers a rapid 50mg caffeine dose via single-serving stick packs in four flavors and features new branding and a redesigned mobile website for direct purchase.
Aspire Biopharma (Nasdaq:ASBP) subsidiary Buzz Bomb Caffeine Company signed a strategic brand management and distribution agreement with Blue Shark Beverages, effective February 1, 2026, to expand BUZZ BOMB™ retail placement across Southern California.
The rollout debuts in Palm Springs and Coachella Valley, then phases into Los Angeles and San Diego, targeting resorts, hotels, casinos, festival channels and broader retail outlets.
Aspire Biopharma (Nasdaq:ASBP) has signed an agreement with Microsize to support development of a 162 mg sublingual aspirin powder for emergency treatment of suspected acute myocardial infarction. The collaboration targets optimized drug product for an upcoming clinical trial and a planned Section 505(b)(2) NDA submission near end of 2026.
The clinical study will compare serum thromboxane B2 inhibition in 32 healthy volunteers versus two chewed 81 mg aspirin tablets; Microsize will provide cGMP micronization and particle‑engineering services to advance formulation and commercial manufacturing readiness.
Aspire Biopharma (Nasdaq:ASBP) announced filing a provisional patent application with the USPTO for the first-ever sublingual powder formulation of clopidogrel.
The filing covers a sublingual delivery system intended to improve clopidogrel pharmacokinetics by enabling absorption under the tongue, potentially increasing bioavailability and reducing or eliminating gastric irritation associated with oral tablets. Aspire plans to pursue commercialization via the FDA 505(b)(2) pathway and positions this program alongside its other reformulation efforts, including an investigational acetylsalicylic acid 162 mg sublingual powder (OTASA) intended for emergency myocardial infarction treatment.
Aspire Biopharma (NASDAQ:ASBP) announced delivery of two million units of its flagship caffeine supplement BUZZ BOMB™ on January 22, 2026, and strategic inventory of 100,000 20-packs now available to meet demand. The rollout includes a modernized brand identity, redesigned high-impact packaging, an emphasis on 50mg precise dosing and near-instant sublingual absorption, and a new e-commerce storefront. Aspire plans an aggressive growth push via expanded digital marketing, influencer partnerships, DTC optimization, and evaluation of retail and wholesale channels to scale the consumer business.
Aspire Biopharma (NASDAQ:ASBP) announced a comprehensive brand redesign for its flagship caffeine product, BUZZ BOMB™ on January 21, 2026. The initiative includes a new logo, a mobile‑optimized e-commerce website at https://buzzbombcaffeine.com, and redesigned packaging with a vibrant aesthetic to emphasize rapid, sustained focus and sublingual delivery.
The website offers a streamlined shopping experience, product information, promotions, and educational content. Management says the redesign aims to improve customer engagement, showcase the product's capabilities, and position BUZZ BOMB for growth.
Aspire Biopharma (NASDAQ:ASBP) filed a provisional patent application for a first-ever sublingual powder formulation of alprazolam, aiming to improve bioavailability and accelerate onset versus oral tablets. The filing covers a sublingual delivery system designed to absorb alprazolam under the tongue to bypass first-pass metabolism and potentially shorten onset from about 30 minutes to minutes.
The company said it plans a Phase 1 clinical trial in mid-2026 and intends to pursue commercialization via the FDA 505(b)(2) pathway. Aspire framed this program as part of a broader pipeline of reformulated approved therapeutics targeting patients needing rapid relief or who have difficulty swallowing.